Member Info for Dystopian

Hi Westernglory- looks like you've got the answer you were looking for......

I'm curious as to why they have gone with Cairn- by the look of the website etc , obviously to save money. I notice Cairn also

advise Valirx- this company is the most badly managed sh*t show of a biopharma I know- anyone who puts money into it does not understand this market. Anyhow, there are reasons they've gone this way so I guess its, lets see what happens from now on. To me its all about the biology , so roll on April for the next set of trial updates.

Howard249 , I fully endorse what you say re. research into the company etc, Too many investors buy into biphama and have no idea of the multiple hoops that have to be jumped through to get anywhere near a license and the sheer amount of time and money required. Also investors think " their " company is a special case and the FDA et al are just going to roll over and grant a license on a small amount of data. There are dozens of outfits similar to Faron, however , as a long term investor I do believe Faron are a pretty professional bunch and do have a team with serious credentials . RE the traumakine crash , they did what anyone else would have done to remain afloat , so credit due. I'm here to the end even if it is 3 years ( hopefully not ..) before I can breath easy...

You are not being cynical- more like hard headedly realistic. Biopharma investment is a high risk game, where the investors have to constantly decipher the BS spun out by the management. I have direct experience of this with Faron, I was well invested in 2017, they knew damn well in December 2017 that Traumakine had failed P3 but carried on until May 2018 as if it was a done deal. Eventually they had to release the data and the rest is history. I do though give Marku credit for saving the company through application of some pretty low cunning. Ie buying time and getting a share option done in Feb 2018, when he knew it was all over.....

For any of you long term holders out there who's been missing Zengahs " erudite and well researched posts"- its looks like you're in luck.......

I think SMT saw this one coming a while back ........

Looks like the SAB has had a bit of a clear out - longstanders eg J Knowles seems to have gone but is still on the website as of now.

It's dangerous ground re getting rid of managers- its a bit like canning football managers- you never really know what effects you're going to unleash. It may signify a measure of desperation or a timely re-set....who knows...

The holding is actually far less than I thought ...... probably not worth worrying about.

Looks like Northvolt is going down the pan, its not a massive part of the portfolio , but it is a significant unlisted component- what impact will this have ? Answers on a postc.......

At least Farn has held firm this week alongside all the other Tech/ Biotek stocks which have gone belly up- hopefully temporarily- Moderna anyone ? - .......

I'm with you on this one Drac, Faron have treated the smaller long term investors apallingly over the so called "hiccup"- SP has not recovered to any significant extent, - some kind of explanation is the least we deserve. Maybe the larger institutional investors were given some some kind of reassurance and promise it would soon recover but we will never know..

Its worth pointing out that Gilead bought Forty Seven to get hold of Magrolimab , which at the time- 4 years ago- had gone through a promising phase 1B , for myelodysplastic syndrome (MDS) and acute myeloid leukemia What happened next is that the FDA approved a phase 2 , and subsequently a phase 3 for these conditions- they did not expedite any accelerated programme despite there being an unmet need scenario. This was in the face of serious lobbying from Gilead who are a USA company with a lot of financial clout. If you do your research you will find that The FDA has stopped the phase 3 trials https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml. This is due to a higher death rate in the treated cohort. The likelyhood of BEX getting an accelerated trial/ approval with a small cohort is Zero. If they went down this route every time a small phase 1 posted stunning results they would be killing people left right and centre, plus litigation would be unreal. As always a full one properly designed and approved phase 111 - if successful- is what is needed for approval.

Drac, I guess like all CEOs Marku had to put a rather optimistic spin on things but ultimately it just makes new investors very wary and only makes raising funds even more of a white knuckle ride. I would have more respect if CEOs just told it how it is, instead endless jam tomorrow stories..

Any income stream Faron may get from Bex is 4-5 years away- this is the time scale to get through Phase 11, get approval for phase 111, get funded by whatever means possible , run phase 111 and finally get approval and then launch. Realistically the best we can hope for , medium term as investors ( everyones definition of this is different )is a partner to come in which will hopefully push the SP up. Then its decision time- wait for further developments or take profits - whichever way you cut it, its going to take years,-unless phase 11 is absolutely stunning- then a buyout may happen but I doubt it. Meanwhile Faron have a ton of money to raise.

That whole " hiccup " episode does stink. I find it hard to believe an experienced CEO such as Marku ( plus other people in the management team ) who has been involved in commercial Biopharma for a long time , took their eye off the ball and allowed it to happen.

Maybe Nasdaq and NYSE is going to free fall between now and close of play - I doubt it somehow .

I dont get SMT -the major holdings- well the public ones- have had a decent day yet the SP goes down.

For what it’s worth here are a few more thoughts on the current situation. Regards options going forward , it may be that a co development partner comes in , or some kind of rights issue, fund raise etc allows business to go forward- but my personal opinion ( as stated in an earlier post ) is that phase 111 data needs to be seen before big pharma attempts a takeover. The reason I say this is the results so far are encouraging,( but with small numbers ), certainly not stratospheric, no matter what Marku says. I also get the impression that there is still work to be done determining what the best combination therapy might be and which cancer type is best suited to treatment with Bex. This does not necessarily mean a completed Phase 111 trial but at least some interim data with a larger cohort. This of course is just my view , but what I think is much more certain is that a buyout will not happen any time soon at the current SP- Faron cannot let this happen unless they are on the rocks. If you go back over the director share deals then there is the standout deal where Jonathan Knowles bought 63 000 shares at £ 7.25 in 2017. There is no way he has averaged down over the years to anything like this, so takes a big hit if a takeover comes in at 2-3 times current SP which would be a good result in most people’s estimation. Then again how much clout does he have ? – he is the head of the SAB , and formerly on the board of directors but amount in question might be small beer to him . Who knows? Other insiders take a sizable hit as well, until the SP gets back to £ 5-6 .

What I would like to know,- is the current status – blocked bank account- a sort of legal position which is automatically set in motion due to some regulatory rules, and the situation is usually resolved amicably and everything carries on as normal , or is this really bad news with a very uncertain outlook? Any thoughts ? I am in here to the end, and there will be answers one day !

This situation needs clarification asap from Faron. In general the investors in this type of company -ie high risk but potentially high reward are supportive over the years.- The management at Faron have been doing a decent job - they have been a bit less than transparent at time but no less than other boards . Obviously their hand has been forced but as share holders we deserve an explanation and reassurance-soon. If this goes on the SH will drop further which gives Faron fewer options for getting back on track. If no investors are lined up for a share option - or Timo gets nervous then it may come down to a fire sale which leaves everyone up the creek.